Mounjaro (Tirzepatide) for Women in Singapore: Efficacy, Safety & What to Know
Weight Loss
Min Read

Mounjaro (Tirzepatide) for Women in Singapore: Efficacy, Safety & What to Know

At a glance

Medically reviewed by Dr. Kevin Chua, Medical Director

Disclaimer: This article provides general medical information and is not a substitute for professional medical advice.


Introduction

Tirzepatide (Mounjaro) has produced the highest weight loss results in clinical trials — an average of 21% body weight at the maximum dose1. For women struggling with weight, these results represent a significant advance. This guide covers women-specific aspects of tirzepatide treatment.


Why Tirzepatide Stands Out for Women

Tirzepatide's dual GLP-1/GIP mechanism offers women several advantages:

  • Superior weight loss — average 21% vs ~15% for semaglutide1
  • Improved insulin sensitivity — particularly beneficial for women with PCOS
  • Metabolic improvements — blood pressure, lipids, and inflammatory markers
  • Potentially better GI tolerability — some studies suggest lower nausea rates than semaglutide

Women in SURMOUNT Trials

Women comprised approximately 67% of SURMOUNT-1 participants. Key findings:

  • Women achieved weight loss comparable to the overall population
  • No gender-specific safety concerns identified
  • Improvements in metabolic health markers were consistent across genders
  • Dose-response relationship was maintained in women

Women-Specific Considerations

The same hormonal considerations apply to tirzepatide as to semaglutide.

Contraception

Tirzepatide delays gastric emptying and may affect oral contraceptive absorption. Women on the pill should discuss alternative contraception with their doctor.

Pregnancy

Contraindicated during pregnancy. Stop tirzepatide before trying to conceive — follow your doctor's guidance on timing (typically at least 2 months).

PCOS

The insulin-sensitising effects of tirzepatide may be particularly beneficial for women with PCOS, though specific PCOS trials are ongoing(Based on MOH guidelines and prescribing information).


Cost in Singapore (SGD)

GLP-1 receptor agonist medications for weight management in Singapore typically cost SGD $200–500 per month depending on the specific medication and dosage. zoey™ offers structured weight management plans with ongoing doctor oversight and support.

Prices are approximate and may vary. Updated April 2026.

FAQ

1. Is Mounjaro stronger than Ozempic for women?

Clinical data suggests greater average weight loss with tirzepatide vs semaglutide. Your zoey™ doctor will recommend the best option based on your specific profile.

2. Are side effects worse with Mounjaro?

GI side effects are common with both medications. Some data suggests Mounjaro may have somewhat lower nausea rates, but individual responses vary.

3. Can I use Mounjaro if I have PCOS?

Yes, and it may be particularly beneficial. The dual mechanism improves insulin sensitivity, a core issue in PCOS.

4. Is Mounjaro available in Singapore?

Mounjaro has HSA registration. Availability may vary due to global supply. Your zoey™ doctor can advise on current access.

5. How does the cost compare?

Mounjaro is similarly priced to Wegovy (S$400–650/month), though pricing varies by dose and supply.


References


→ Return to pillar: Complete Guide to Medical Weight Loss for Women

This article is for informational purposes only and does not constitute medical advice. Always consult a licensed doctor before starting any treatment.


  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024 

Find out what your BMI indicates

Your BMI indicates that you may be
Slider
BMI provides an estimate of weight classification. For a thorough analysis of your weight and medical options, arrange a teleconsult with a Noah doctor.

*Medical treatment may not be appropriate for you even if you have a high BMI
Your estimated weight loss in 1 year*
-
00
kg
-9%
90
kg
78
kg
99
81
63
Transparent weight loss progress graph illustration showing body weight reduction over time on a treatment programme
*In a 56-week trial with 3,731 non-diabetic overweight (BMI ≥27) or obese (BMI ≥30) participants, those who finished (1,812 patients) lost an average of 9.2% body weight with Saxenda, alongside diet and exercise.
medically reviewed by
Dr. Kevin Chua, Medical Director
Written by our
last updated
April 7, 2026
DISCLAIMER

Articles featured on Zoey are for informational purposes only and should not be constituted as medical advice, diagnosis or treatment. If you have any medical questions or concerns, please talk to your healthcare provider. If you're looking for a healthcare provider, click here.

Arrow square up-right icon representing external links on the Zoey SG website
References
No items found.